Company / Free Cash Flow
Inhibrx Biosciences, Inc. Free Cash Flow History
FY2023-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Free Cash Flow
-$129.8M
FY2025
5-year range
-$197.9M / -$129.8M
FY2023-FY2025
Trend
+34.4%
vs FY2024
Sector context
#121 of 194
Health Care
What the data says
At -$130M, Inhibrx Biosciences, Inc.'s free cash flow ranks #121 of 194 in the Health Care sector. Improved from -$198M to -$130M over the past 2 years.
Based on SEC 10-K filings.
-$130M in FY2025.
Improved from -$198M to -$130M over the past 2 years.
Health Care sector context is included.
Free Cash Flow over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#121 of 194 in Health CareTop 62% of 194This company -$129.8M Sector average $470.6M
▼
-127.6% below sector average
Key checks
Key Insights
- In FY2025, free cash flow increased 34.4% year-over-year.
- Ranks #121 out of 194 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score -3.77 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Free Cash FlowValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$129.8M | +34.4% |
| FY2024 | -$197.9M | +0.0% |
| FY2023 | -$197.9M | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026